CN113316578A - 杂环化合物、包含其的药物组合物及其制备方法和用途 - Google Patents

杂环化合物、包含其的药物组合物及其制备方法和用途 Download PDF

Info

Publication number
CN113316578A
CN113316578A CN202080009954.2A CN202080009954A CN113316578A CN 113316578 A CN113316578 A CN 113316578A CN 202080009954 A CN202080009954 A CN 202080009954A CN 113316578 A CN113316578 A CN 113316578A
Authority
CN
China
Prior art keywords
compound
group
radical
cycloalkyl
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080009954.2A
Other languages
English (en)
Other versions
CN113316578B (zh
Inventor
陈忠辉
段霜霜
李桂英
韩润丰
孙启正
景连栋
韩晓军
田强
宋宏梅
薛彤彤
王晶翼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Original Assignee
Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Kelun Biotech Biopharmaceutical Co Ltd filed Critical Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Priority to CN202311264080.7A priority Critical patent/CN117327078A/zh
Priority to CN202311221283.8A priority patent/CN117263945A/zh
Publication of CN113316578A publication Critical patent/CN113316578A/zh
Application granted granted Critical
Publication of CN113316578B publication Critical patent/CN113316578B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/504Pyridazines; Hydrogenated pyridazines forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

本发明涉及杂环化合物、包含其的药物组合物及其制备方法和用途。具体而言,本发明的化合物由式(I)表示,其用于预防或治疗与RET活性相关的疾病或病况。

Description

PCT国内申请,说明书已公开。

Claims (12)

  1. PCT国内申请,权利要求书已公开。
CN202080009954.2A 2019-02-19 2020-02-11 杂环化合物、包含其的药物组合物及其制备方法和用途 Active CN113316578B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202311264080.7A CN117327078A (zh) 2019-02-19 2020-02-11 杂环化合物、包含其的药物组合物及其制备方法和用途
CN202311221283.8A CN117263945A (zh) 2019-02-19 2020-02-11 杂环化合物、包含其的药物组合物及其制备方法和用途

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN2019101245846 2019-02-19
CN201910124584 2019-02-19
CN201910437878 2019-05-24
CN2019104378784 2019-05-24
CN2019109320953 2019-09-29
CN201910932095 2019-09-29
PCT/CN2020/074696 WO2020168939A1 (zh) 2019-02-19 2020-02-11 杂环化合物、包含其的药物组合物及其制备方法和用途

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202311264080.7A Division CN117327078A (zh) 2019-02-19 2020-02-11 杂环化合物、包含其的药物组合物及其制备方法和用途
CN202311221283.8A Division CN117263945A (zh) 2019-02-19 2020-02-11 杂环化合物、包含其的药物组合物及其制备方法和用途

Publications (2)

Publication Number Publication Date
CN113316578A true CN113316578A (zh) 2021-08-27
CN113316578B CN113316578B (zh) 2023-10-31

Family

ID=72143544

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202311264080.7A Pending CN117327078A (zh) 2019-02-19 2020-02-11 杂环化合物、包含其的药物组合物及其制备方法和用途
CN202311221283.8A Pending CN117263945A (zh) 2019-02-19 2020-02-11 杂环化合物、包含其的药物组合物及其制备方法和用途
CN202080009954.2A Active CN113316578B (zh) 2019-02-19 2020-02-11 杂环化合物、包含其的药物组合物及其制备方法和用途

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CN202311264080.7A Pending CN117327078A (zh) 2019-02-19 2020-02-11 杂环化合物、包含其的药物组合物及其制备方法和用途
CN202311221283.8A Pending CN117263945A (zh) 2019-02-19 2020-02-11 杂环化合物、包含其的药物组合物及其制备方法和用途

Country Status (14)

Country Link
US (1) US20220144847A1 (zh)
EP (1) EP3929198A4 (zh)
JP (1) JP2022521859A (zh)
KR (1) KR20210131314A (zh)
CN (3) CN117327078A (zh)
AU (1) AU2020226422A1 (zh)
BR (1) BR112021016299A2 (zh)
CA (1) CA3130245A1 (zh)
CL (1) CL2021002205A1 (zh)
CO (1) CO2021011023A2 (zh)
IL (1) IL285378A (zh)
MX (1) MX2021009971A (zh)
SG (1) SG11202107848TA (zh)
WO (1) WO2020168939A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112023000065A2 (pt) * 2020-07-28 2023-01-31 Sichuan Kelun Biotech Biopharmaceutical Co Ltd Sal e forma cristalina de composto de pirimidina e métodos de preparação para os mesmos
CN116801882A (zh) 2021-03-24 2023-09-22 四川科伦博泰生物医药股份有限公司 杂环化合物治疗与激酶耐药突变相关的疾病的用途和方法
CN114235976B (zh) * 2021-11-09 2023-11-03 暨南大学 一种含氮杂环有机化合物中间产物的合成和分析方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101166734A (zh) * 2005-02-28 2008-04-23 日本烟草产业株式会社 具有Syk抑制活性的新型的氨基吡啶化合物
WO2012154518A1 (en) * 2011-05-10 2012-11-15 Merck Sharp & Dohme Corp. Bipyridylaminopyridines as syk inhibitors
CN103298788A (zh) * 2010-10-28 2013-09-11 日本新药株式会社 吡啶衍生物及医药

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010208945A (ja) * 2007-06-01 2010-09-24 Mitsubishi Tanabe Pharma Corp 複素環化合物
JP2013107824A (ja) * 2010-03-17 2013-06-06 Dainippon Sumitomo Pharma Co Ltd 新規単環ピリミジン誘導体
IL302209B2 (en) 2015-11-02 2024-06-01 Blueprint Medicines Corp RET inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101166734A (zh) * 2005-02-28 2008-04-23 日本烟草产业株式会社 具有Syk抑制活性的新型的氨基吡啶化合物
CN103298788A (zh) * 2010-10-28 2013-09-11 日本新药株式会社 吡啶衍生物及医药
WO2012154518A1 (en) * 2011-05-10 2012-11-15 Merck Sharp & Dohme Corp. Bipyridylaminopyridines as syk inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LI BING KE 等: "In Silico Prediction of Spleen Tyrosine Kinase Inhibitors Using Machine Learning Approaches and an Optimized Molecular Descriptor Subset Generated by Recursive Feature Elimination Method", 《COMPUTERS IN BIOLOGY AND MEDICINE》 *
吴姗姗: "《STN》", 15 July 2022 *

Also Published As

Publication number Publication date
CN117263945A (zh) 2023-12-22
CL2021002205A1 (es) 2022-04-22
US20220144847A1 (en) 2022-05-12
IL285378A (en) 2021-09-30
CO2021011023A2 (es) 2021-09-09
WO2020168939A1 (zh) 2020-08-27
CN117327078A (zh) 2024-01-02
SG11202107848TA (en) 2021-08-30
EP3929198A1 (en) 2021-12-29
MX2021009971A (es) 2021-10-13
BR112021016299A2 (pt) 2021-10-13
KR20210131314A (ko) 2021-11-02
CN113316578B (zh) 2023-10-31
EP3929198A4 (en) 2022-11-16
JP2022521859A (ja) 2022-04-12
CA3130245A1 (en) 2020-08-27
AU2020226422A1 (en) 2021-09-09

Similar Documents

Publication Publication Date Title
KR102368439B1 (ko) 1,4-이치환된 피리다진 유사체 및 smn-결핍-관련 상태의 치료 방법
CN113316578A (zh) 杂环化合物、包含其的药物组合物及其制备方法和用途
CN113950481A (zh) 大环化合物
CN113330009B (zh) 氮杂环化合物、其制备方法及用途
KR101921486B1 (ko) PARP억제제인 4H-피라졸로[1,5-a]벤즈이미다졸 화합물의 아날로그
BR112021011147A2 (pt) Benzamidas de derivados de pirazolil-amino-pirimidinila e composições e métodos das mesmas
CN111285882A (zh) 稠环化合物、包含其的药物组合物及其制备方法和用途
CN113993861B (zh) 吡唑基-氨基-嘧啶基衍生物的苯醚和苯胺及其组合物和方法
WO2020186220A1 (en) Compounds as inhibitors of macrophage migration inhibitory factor
CN114096545A (zh) 新杂环化合物
CN111484479A (zh) 氮杂环化合物、包含其的药物组合物及其制备方法和用途
CN112574201B (zh) 芳基胺类化合物、包含其的药物组合物及其制备方法和用途
JP7511294B2 (ja) Fgfr阻害剤化合物及びその使用
KR20240043754A (ko) 신규 parp7 억제제 및 이의 용도
CN114621186A (zh) 作为ras信号通路调控剂的杂环化合物
CN115043844B (zh) Trk激酶抑制剂化合物及其用途
JP2024511389A (ja) キナーゼ薬剤耐性変異に関連する疾患を治療するための複素環式化合物の使用及び方法
EP4389738A1 (en) Sos1 inhibitor and use thereof
AU2013302859B9 (en) 1,4-disubstituted pyridazine analogs and methods for treating SMN-deficiency-related conditions
JP2024528021A (ja) 新規なparp7阻害剤及びその使用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40051009

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant